DocWire News Editors

DocwireNews

By inserting a single gene for a green light receptor into the eyes of blind mice, scientists from the University of California, Berkeley, were able to restore their vision. These effects were observed one month after genetic alteration, with the mice navigating around obstacles as easily as the mice with no history of visual defects. They were also able to detect motion, brightness changes and fine detail on a screen to distinguish letters.To correct the blindness in these mice, the researchers created a virus that targeted retinal ganglion cells and equipped it with the gene for the green cone opsin, a light-sensitive receptor. This opsin is normally expressed by cone photoreceptor cells that allow them to detect green-yellow light. Injecting this into the eye allowed the virus to encode this gene into the ganglion cells that normally are not light sensitive. Doing so transformed these cells to be light-sensitive and enabled them to send signals to the brain that were interpreted as vision.<a href="https://proddocwire.wpengine.com/docwire-pick/future-of-medicine-picks/antifungal-drug-could-function-as-an-effective-treatment-for-cystic-fibrosis/">READ MORE:&nbsp;Antifungal Drug Could Function as an Effective Treatment for Cystic Fibrosis</a>The utility of this injection method is that it can be done easily through the eye. The earlier versions of such viral therapy required the injecting of viruses underneath the retina. This means of gene therapy uniquely transforms non-visual cells in the retina to takeover the light-sensing function of the rods and cones.<img loading="lazy" decoding="async" class=" wp-image-4810837 aligncenter" src="https://mumcdnstorage.blob.core.windows.net/dwnews/2019/03/mouse-box495-1.jpg" alt="" width="434" height="410">The researchers claim that in as little as three years, the gene therapy could be used in trials in humans who have lost vision due to retinal degeneration. Ideally, this would give these patients enough vision to move around and potentially be able to read or watch video.&ldquo;You would inject this virus into a person&rsquo;s eye and, a couple months later, they&rsquo;d be seeing something,&rdquo; said Ehud Isacoff, UC Berkeley professor of molecular and cell biology and director of the Helen Wills Neuroscience Institute. &ldquo;With neurodegenerative diseases of the retina, often all people try to do is halt or slow further degeneration. But something that restores an image in a few months &mdash; it is an amazing thing to think about.&rdquo;With roughly 170 million people living with age-related macular degeneration and 1.7 million having retinitis pigmentosa, the most common form of heritable blindness, gene therapy that could restore vision in patients would have a profound impact in this community.The existing treatment option for these patients is currently an electronic eye implant that is connected to a video camera on a pair of glasses. This tool produces an image on the retina that is roughly a few hundred pixels, whereas millions of pixels are required for sharp vision. In addition to yielding low quality images, these glasses are bulky, invasive, and expensive as well.In the mice, the researchers were able to administer the opsins to most of the retinal ganglion cells, but in humans they will need to inject many more of the virus since the human eye has many more of these ganglion cells. The UC Berkeley team has developed methods to enhance viral delivery and hopes to insert the gene in a high percentage of ganglion cells that will compare to the high pixel numbers in a camera.<a href="https://proddocwire.wpengine.com/docwire-pick/future-of-medicine-picks/fda-approves-ketamine-derived-nasal-spray-treatment-for-depression/">READ MORE:&nbsp;FDA Approves Ketamine-Derived Nasal Spray Treatment for Depression</a>Alongside fellow UC Berkeley professor John Flannery, Isacoff is raising funds to apply this gene therapy in human trials in the next three years. Similar adeno-associated virus delivery systems have been approved by the FDA in treating visual defects, and the team hopes to add their gene therapy to this list.&ldquo;That this system works is really, really satisfying, in part because it&rsquo;s also very simple,&rdquo; Isacoff said. &ldquo;Ironically, you could have done this 20 years ago.&rdquo;<blockquote class="twitter-tweet" data-lang="en">
A single gene insertion is allowing blind mice to see again &ndash; <a href="https://t.co/6vTFHXyFDZ">https://t.co/6vTFHXyFDZ</a> via <a href="https://twitter.com/ScienceDaily?ref_src=twsrc%5Etfw">@ScienceDaily</a> <a href="https://t.co/oW0Lp0FD7Q">pic.twitter.com/oW0Lp0FD7Q</a>
&mdash; Science Node&trade; (@SciNode) <a href="https://twitter.com/SciNode/status/1106628126891610112?ref_src=twsrc%5Etfw">March 15, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Sources: <a href="https://news.berkeley.edu/wp-content/uploads/2019/03/Intravitreal-injection-diagram750.jpg">UC Berkeley</a>

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

UC Berkeley Researchers Restore Vision in Blind Mice with Single Gene Injection

Future of Medicine

By inserting a single gene for a green light receptor into the eyes of blind mice, scientists from the University of California, Berkeley, were able to restore their vision. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe